BUHLMANN Citations Archives - Page 12 of 14 - Buhlmann Diagnostics Corp

Category: BUHLMANN Citations

A number of the publications in the citation list describe applications that are outside of product claims thus they should be used for information only.

Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance IFX Therapy

Quantum Blue® fCAL Citation: Ferreiro-Iglesias, R. Barreiro-de Acosta M, Otero Santiago M, Lorenzo Gonzalez A, Alonso de la Peña C, Benitez Estevez AJ, Dominguez-Muñoz JE., Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance IFX Therapy. J Clin Gastroenterol. 2016 Feb;50(2):147-51. doi: 10.1097/MCG.0000000000000312. Highlight from this Publication “We found FC to
Continue Reading

Fecal Calprotectin Predicts Relapse and Histological Mucosal Healing in Ulcerative Colitis

BÜHLMANN fCAL® ELISA Citation Theede, K. ,Holck S, Ibsen P, Kallemose T, Nordgaard-Lassen I, Nielsen AM. Fecal Calprotectin Predicts Relapse and Histological Mucosal Healing in Ulcerative Colitis, Inflamm Bowel Dis. 2016 May;22(5):1042-8. doi: 10.1097/MIB.0000000000000736. Highlights from this Publication “…our histological inflammatory activity score is closely related to the concentration of FC and thereby has the advantage
Continue Reading

Fecal Level of Calprotectin Identifies Histologic Inflammation in Patients with Ulcerative Colitis In Clinical And Endoscopic Remission

BÜHLMANN fCAL® ELISA Citation Guardiola, J, Schatt P, Grimmelprez A, Gohy P, Deltour D, Collard G, Vankerkhoven P.  Fecal Level of Calprotectin Identifies Histologic Inflammation in Patients with Ulcerative Colitis In Clinical And Endoscopic Remission, Clinical Gastroenterology and Hepatology.  2014 Nov;12(11):1865-70. doi: 10.1016/j.cgh.2014.06.020. “…an FC value less than 155 mg/g is a reliable indicator of the
Continue Reading

Comparison of the Liaison® Calprotectin Kit with a Well-Established Point of Care Test (Quantum Blue — Bühlmann-Alere®) in Terms of Analytical Performances and Ability to Detect Relapses Amongst a Crohn Population in Follow-up

Quantum Blue®  fCAL Citation: Delefortrie, Q. Schatt P, Grimmelprez A, Gohy P, Deltour D, Collard G, Vankerkhoven P. Comparison of the Liaison® Calprotectin kit with a well-established point of care test (Quantum Blue — Bühlmann-Alere®) in terms of analytical performances and ability to detect relapses amongst a Crohn population in follow-up, Clinical Biochemistry. 2016 Feb;49(3):268-73. doi: 10.1016/j.clinbiochem.2015.10.010
Continue Reading

Comparison of Fecal Inflammatory Markers in Crohn’s Disease

BÜHLMANN fCAL® ELISA Citation Wright, E. K., et al., 2016, Comparison of Fecal Inflammatory Markers in Crohn’s Disease, Inflamm Bowel Dis. 2016 May;22(5):1086-94. doi: 10.1097/MIB.0000000000000671. “This study shows that FC is the optimal marker for diagnosing and monitoring endoscopic postoperative Recurrence”. Learn More
Continue Reading

Measurement of Fecal Calprotectin Improves Monitoring and Detection of Recurrence of Crohn’s Disease After Surgery

BÜHLMANN fCAL® ELISA Citation Wright, E. K., , Kamm MA, De Cruz P, Hamilton AL et. al. Measurement of Fecal Calprotectin Improves Monitoring and Detection of Recurrence of Crohn’s Disease After Surgery, Gastroenterology 2015 May;148(5):938-947.e1. doi: 10.1053/j.gastro.2015.01.026. Highlights from this Publication “The present study has shown that FC concentration is sufficiently sensitive to monitor for recurrence of
Continue Reading

Rapid Fecal Calprotectin Level Assessment and the SIBDQ Score Can Accurately Detect Active Mucosal Inflammation in IBD Patients in Clinical Remission: a Prospective Study,

Quantum Blue® fCAL Citation: Voiosu T Benguş A, Dinu R, Voiosu AM, Bălănescu P, Băicuş C, Diculescu M, Voiosu R, Mateescu B.  Rapid Fecal Calprotectin Level Assessment and the SIBDQ Score Can Accurately Detect Active Mucosal Inflammation in IBD Patients in Clinical Remission: a Prospective Study, J Gastrointestin Liver Dis.  2014 Sep;23(3):273-8. doi: 10.15403/jgld.2014.1121.233.thv. Highlight from
Continue Reading

Prospective Evaluation of the Predictive Value of Faecal Calprotectin in Quiescent Crohn’s Disease

BÜHLMANN fCAL® ELISA Citation Naismith, Smith LA, Barry SJ, Munro JI, Laird S, Rankin K, Morris AJ, Winter JW, Gaya DR. A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn’s disease. J Crohns Colitis. 2014 Sep;8(9):1022-9. doi: 10.1016/j.crohns.2014.01.029. Highlights from this Publication “The FC result, obtained by non-invasive means, can provide prognostic information
Continue Reading

Estimation of the Possible Economic Effects of Pre-Endoscopic Screening with F-calprotectin, Clinical Biochemistry

BÜHLMANN fCAL® ELISA Citation: Mindemark, M. & Larsson, A. Ruling out IBD: Estimation of the possible economic effects of pre-endoscopic screening with F-calprotectin, Clinical Biochemistry. Clin Biochem. 2012 May;45(7-8):552-5. doi: 10.1016/j.clinbiochem.2011.10.015.

Highlights from this Publication:

“The estimated demand for colonoscopies was reduced by 50% to 67%. This corresponded to a cost avoidance of approximately up toa cost avoidance of approximately up to €2.13 million.”
Continue Reading

Fecal Calprotectin is Equally Sensitive in Crohn’s Disease Affecting the Small Bowel and Colon

BÜHLMANN fCAL® ELISA Citation: Jensen, M.D., Kjeldsen J, Nathan T. Fecal calprotectin is equally sensitive in Crohn’s disease affecting the small bowel and colon. Scand J Gastroenterol. 2011 Jun;46(6):694-700. doi: 10.3109/00365521.2011.560680.

Highlights from this Publication:

“The first study to show that fecal calprotectin is equally sensitive in colonic and small bowel CD.”
Continue Reading